[Gli1 expression and its relationship with the expression of Shh, Vimentin and E-cadherin in human hepatocellular carcinoma].

AIM: To investigate the expression and clinical features of glima-associated oncogene 1(Gli1) and its correlation with the expression of sonic hedgehog(Shh), one of the ligands of hedgehog (Hh) signaling, and two epithelial-mesenchymal transition (EMT) markers, Vimentin and E-cadherin in human hepatocellular carcinoma(HCC). METHODS: Paired HCC and normal tumor-adjacent tissues were collected from 63 HCC patients. Gli1 expression at both the protein and mRNA level were examined by immunohistochemistry and RT-PCR. The protein expression of Shh, Vimentin and E-cadherin were evaluated by immunohistochemistry to identify correlations with Gli1. RESULTS: The protein and mRNA expression of Gli1 were significantly up-regulated in the HCC tumor tissues compared to the normal tumor-adjacent tissues. Gli1 protein expression in HCC was closely correlated with intrahepatic metastases (x(2);=6.205, P<0.05), portal vein invasion (x(2);=4.014, P<0.05), high Edmonson-Steiner classification (x(2);=19.668, P<0.05) and advanced TNM stage (x(2);=7.091, P<0.05). Gli1 protein expression was positively correlated with Shh (r=0.574, P<0.05) and Vimentin(r=0.467, P<0.05), and negatively correlated with E-cadherin (r=-0.439, P<0.05). CONCLUSION: Gli1 is up-regulated in HCC tissues and closely correlated with clinicopathological characteristics, the increased expression of Gli1 in HCC tissues may be attributed to Shh, and Gli1 may play an important role in HCC progression and metastasis by inducing EMT.

[UbcH10 expression in hepatocellular carcinoma and its clinicopathological significance].

OBJECTIVE: To investigate UbcH10 expression in hepatocellular carcinoma and explore its clinicopathological implications. METHODS: We detected UbcH10 mRNA expression using RT-PCR in normal liver cell line, cancer cell lines, surgically removed hepatocellular carcinoma tissue and corresponding adjacent non-tumor tissue and evaluated the clinicopathological significance of UbcH10. Immunohistochemistry was performed to investigate UbcH10 protein expression in hepatocellular carcinoma tissue, the adjacent tissue, and normal liver tissue specimens. RESULTS: Normal liver cell line L02 showed significantly lower UbcH10 mRNA expression levels than the cancer cell lines BEL-7402, Hep3B, HepG2 and SMMC-7721 (P<0.05). UbcH10 mRNA expression was also was significantly higher in hepatocellular carcinoma tissues than in the corresponding non-tumor tissues (P<0.05). Clinicopathological evaluation suggested that UbcH10 expression was associated with tumor invasion of the portal vein, tumor size, TNM staging, and tumor differentiation (P<0.05). Immunohistochemistry identified stronger UbcH10 expression in hepatocellular carcinoma tissues than in the adjacent tissues and normal liver tissues (68.6%, 28.6%, and 26.7%, respectively). CONCLUSION: UbcH10 is over-expressed in hepatocellular carcinoma and may serve as a novel biomarker as well as a therapeutic target of hepatocellular carcinoma.